Announcement on Providing Guarantee for Controlled Subsidiary
Filed with SSE · · 6 pages · Chinese
Dizal (Jiangsu) Pharmaceutical Co. Ltd. on 6ix
Earlier from Dizal (Jiangsu) Pharmaceutical
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
- Announcement on Voluntary Disclosure of Semi-annual Performance Forecast for 2026
- Materials for the 2nd Extraordinary General Meeting in 2026
- Announcement on Abnormal Fluctuations in Stock Trading
- Notice on Convening the 2nd Extraordinary General Meeting in 2026
Later from Dizal (Jiangsu) Pharmaceutical
- Announcement on Resolutions of the 1st Meeting of the 3rd Board of Directors
- Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026
- Announcement on Voluntary Disclosure of the Acceptance by the U.S. FDA of the Supplemental New Drug Application for Sunvozertinib as a Monotherapy for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
- Announcement on Shareholding Reduction Plan of Directors and Senior Management
- Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the Innovative Drug Industry
Follow Dizal (Jiangsu) Pharmaceutical into a list and get an email when it puts out news.
Follow Dizal (Jiangsu) Pharmaceutical